The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by JP Morgan on June 9, 2025. The analyst firm set a price target for $800.00 expecting REGN to rise to within 12 ...

JPMorgan lowered the firm’s price target on Regeneron (REGN ... particularly as we near a number of pipeline readouts, the analyst tells investors in a research note. Published first on TheFly ...

Wall Street analysts issued a fresh round of ratings changes on Friday, including notable downgrades for Airbnb (ABNB), Regeneron (REGN), and Cooper Companies (COO), and upgrades for Unity (U) and ...

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy itepekimab, developed with Sanofi (SNY) for a lung disorder known as chronic ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals ... One investment analyst has rated the stock with a sell rating, six have issued a hold rating ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase ... One investment analyst has rated the stock with a sell rating ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating on the shares. The firm adjusted its large cap ...